Valuation: Intervacc AB

Market Cap 443M 45.51M 39.92M 36.85M 34.06M 64.55M 4.36B 65.84M 172M 2.13B 171M 167M 7.4B P/E 2026 *
-5.91x
P/E 2027 * -5.91x
Enterprise Value 350M 35.96M 31.54M 29.12M 26.91M 51M 3.44B 52.02M 136M 1.68B 135M 132M 5.85B EV / Sales 2026 *
19.8x
EV / Sales 2027 * 12.6x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.25%-4.31%+69.81%+124.57% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
-0.38%+0.53%+37.37%-26.26% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average +0.21%+4.02%+56.44%+153.10% 26.6B
Weighted average by Cap. -0.27%+2.20%+57.40%+143.25%

Financials

2026 *2027 *
Net sales 17.7M 1.82M 1.59M 1.47M 1.36M 2.58M 174M 2.63M 6.88M 85.2M 6.83M 6.68M 296M 30.05M 3.09M 2.71M 2.5M 2.31M 4.38M 296M 4.47M 11.68M 145M 11.59M 11.34M 502M
Net income -80.8M -8.3M -7.28M -6.72M -6.21M -11.77M -795M -12.01M -31.39M -389M -31.17M -30.49M -1.35B -83.65M -8.59M -7.54M -6.96M -6.43M -12.19M -823M -12.43M -32.5M -403M -32.27M -31.56M -1.4B
Net Debt -93M -9.55M -8.38M -7.74M -7.15M -13.55M -915M -13.82M -36.14M -448M -35.88M -35.09M -1.55B -63M -6.47M -5.68M -5.24M -4.84M -9.18M -620M -9.36M -24.48M -303M -24.3M -23.77M -1.05B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
-